Related Experiment Video
Updated: Jan 20, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL
Blake A Rowe1, Kimberly J Reese1, Kelly McGrath2
1Immunogenicity Dept., Biomarker & Bioanalytical Platforms (BBP), Platform Sciences, GSK, Collegeville, PA, USA.
Aim:
To develop an anti-drug antibody (ADA) assay for a bispecific antibody (bsAb) we will refer to as Drug-1, and to quantify the ADAs against each specific fragment antigen-binding (Fab) site of Drug-1.
Materials And Methods:
Here we use two additional unlabeled monoclonal antibodies (mAbs) Drug-2 & Drug-3 in an ADA confirmation assay format. Drugs-2 & -3 have the same targets as the two Fabs of Drug-1, facilitating our aim to measure and quantify the anti-drug Abs against each specific Fab of Drug-1 by signal inhibition.
Results And Conclusion:
By using the combination of a screening and a dual confirmation assay format, we were able to accurately quantify the ADAs against each specific Fab of the bsAb Drug-1.
Related Concept Videos
11:13A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
02:44An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
12:55Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
04:20Functional Assessment of Antibody-Secreting B Cells Using ELISpot Assay
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation